Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NVA237 28-day safety and bronchodilator study in moderate to severe COPD
2007-000643-95Phase 2Completed
- Sponsor
- Novartis
- Start
- May 2007
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of glycopyrronium in chronic obstructive pulmonary disease (COPD) (3 arms), sponsored by Novartis. Primary endpoint: Safety and tolerability. Started May 2007; status: completed.
02
Drugs
glycopyrronium
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on 2007-000643-95.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-000643-95.